![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Mouhayar Elie Durand Jean-Bernard Cortes Jorge
Publisher: Informa Healthcare
ISSN: 1474-0338
Source: Expert Opinion on Drug Safety, Vol.12, Iss.5, 2013-09, pp. : 687-696
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Selective tyrosine kinase inhibitors
Expert Opinion on Emerging Drugs, Vol. 5, Iss. 3, 2000-10 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Current Cancer Drug Targets, Vol. 10, Iss. 5, 2010-08 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Tyrosine kinase inhibitors regulate serotonin uptake in platelets
European Journal of Pharmacology, Vol. 280, Iss. 2, 1995-07 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Emerging tyrosine kinase inhibitors for esophageal cancer
By Ku Geoffrey Y Ilson David H
Expert Opinion on Emerging Drugs, Vol. 18, Iss. 2, 2013-06 ,pp. :